BREYANZI® (LISOCABTAGENE MARALEUCEL)

PATIENT CARD

BREYANZI® (LISOCABTAGENE MARALEUCEL)

Bristol Myers Squibb®

BREYANZI®

(LISOCABTAGENE MARALEUCEL)

PATIENT CARD

Bristol Myers Squibb®

Have this card with you at all times. Show it to any doctor/healthcare provider who sees you, including in an emergency.

Tell any healthcare provider who sees you that you are being treated with Breyanzi.

For at least 4 weeks after receiving Breyanzi, you should plan to stay close to the location where you received treatment.

This card and its content have been approved by the Ministry of Health in June 2025

2009-IL-2500001

I have been treated with Breyanzi®

Important Contact Information (PRINT)

My Name:

_____

Name of Breyanzi Treating Physician:

_____

Office/Hospital Phone Number:

_____

After-hours Phone Number:

_____

Hospital Name:

_____

Date of Breyanzi Infusion (DD/MM/YYYY):

_____

Batch Number:

_____

Information for the Healthcare Provider

This patient has received Breyanzi chimeric antigen receptor (CAR)-positive T-cell therapy, a cluster of differentiation (CD)19-directed genetically modified autologous cell-based product consisting of purified CD8+ and CD4+ T cells, in a defined composition, that have been separately transduced *ex vivo* using a replication-incompetent lentiviral vector expressing an anti-CD19 chimeric antigen receptor.

Following treatment with Breyanzi, cytokine release syndrome (CRS) and/or neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), may occur, which may be fatal or life-threatening. Cytokine release syndrome (CRS) may involve any organ system.

Contact patient's Breyanzi treating physician immediately for further information.

Please see Breyanzi's Patient Leaflet and Prescribing Information.

This card and its content have been approved by the Ministry of Health in June 2025

2009-IL-2500001

Adverse reactions may be reported to the Ministry of Health by means of the online form for reporting adverse reactions located on the homepage of the Ministry of Health's website www.health.gov.il or by logging in to https://sideeffects.health.gov.il

You may also report side effects to Bristol Myers Squibb by phone 1809-388054 (a toll-free number) or email Medinfo.Israel@bms.com

Information for Patients

Breyanzi may cause side effects that are severe or life-threatening.

Call your Breyanzi treating physician or go to the emergency room/department immediately if any of the following symptoms appear:

Neurologic Adverse Reactions

The following may be symptoms of ICANS:

- Confusion
- Being less alert (decreased consciousness)
- Difficulty speaking or slurred speech
- Shaking (tremor)
- Feeling anxious
- Feeling dizzy
- Headache

Cytokine Release Syndrome (CRS)

- Fever
- Chills or shaking
- Feeling tired
- Fast or uneven heartbeat
- Feeling light-headed and short of breath
- Low blood pressure (hypotension)

To obtain additional copies of this Patient Card, please contact Bristol Myers Squibb Israel by phone 03-5231021, fax 03-9226896 or email Office_IL@bms.com